Marcos Vidal

Marcos Vidal

Auto-generated profile, based on publicly available information

Marcos Vidal

The Beatson Institute for Cancer Research, Glasgow, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Developmental Cell
Verified
Journal Article
Closed access
JCJulia Cordero
Julia Cordero
JMJuan P. Macagno
Juan P. Macagno
RSRhoda K. Stefanatos
Rhoda K. Stefanatos
KSKaren E. Strathdee
Karen E. Strathdee
RCRoss L. Cagan
Ross L. Cagan
MVMarcos Vidal
Marcos Vidal

4 September 2012 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JCJulia Cordero
Julia Cordero
RSRhoda K Stefanatos
Rhoda K Stefanatos
ASAlessandro Scopelliti
Alessandro Scopelliti
MVMarcos Vidal
Marcos Vidal
OSOwen Sansom
Owen Sansom
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


4 December 2011 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ESEmma Sandilands
Emma Sandilands
BSBryan Serrels
Bryan Serrels
DMDavid G. McEwan
David G. McEwan
JMJennifer P Morton
Jennifer P Morton
JMJuan Pablo Macagno
Juan Pablo Macagno
MFMargaret C. Frame
Margaret C. Frame

1 March 2003 in AIDS
Verified
Journal Article
Closed access
Mario CozzolinoMario Cozzolino
Mario Cozzolino
MVMarcos Vidal
Marcos Vidal
MAMaria Vittoria Arcidiacono
Maria Vittoria Arcidiacono
PTPablo Tebas
Pablo Tebas
KYKevin E Yarasheski
Kevin E Yarasheski
ADAdriana S Dusso
Adriana S Dusso
A high prevalence of bone demineralization occurs in people living with HIV/AIDS. The contribution of HIV itself and its treatment is still unclear. Protease inhibitors (PIs) are potent inhibitors of the cytochrome p450 enzyme system. Three cytochrome p450 mixed function oxygenases control serum levels of 1,25-dihydroxyvitamin D (1,25(OH) D ), which is responsible for vitamin D actions in target tissues including bone. The 25- and 1alpha-hydroxylases regulate 1,25(OH) D synthesis and 24-hydroxylase 1,25(OH) D catabolism. To assess whether HIV-protease inhibitors (ritonavir, indinavir, nelfinavir) impair the activity of the main enzymes involved in 1,25(OH) D homeostasis. Studies were conducted in the human hepatocyte (H3B)- and monocyte (THP-1) cell lines, expressing 25-hydroxylase and 1alpha-hydroxylase, respectively. The 24-hydroxylase expression was induced in macrophages by exposure to 1,25(OH) D. Conversion rates of vitamin D to 25-hydroxyvitamin D [25(OH)D ]; 25(OH)D to 1,25(OH) D or 24,25(OH) D, and 1,25(OH) D degradation were quantified in untreated and HIV-PI-treated cells after C -cartridge extraction and high-performance liquid chromatography purification of 25(OH)D - 24,25(OH) D - and 1,25(OH) D fractions. The PIs impair hepatocyte 25(OH)D - and macrophage 1,25(OH) D synthesis in a reversible, dose-dependent manner. Furthermore, PIs inhibit 1,25(OH) D -degradation in macrophages with lower potency than that elicited on 1alpha-hydroxylase. Thus, reduced macrophage 1,25(OH) D production is the net effect of PIs action. In intact cells, HIV-PIs markedly suppress the activities of 25- and 1alpha-hydroxylase, which are critical in 1,25(OH) D synthesis, while exerting mild inhibition of 24-hydroxylase, responsible for 1,25(OH) D catabolism. If PIs elicit a similar potency in inhibiting these critical steps for 1,25(OH) D homeostasis, defective 1,25(OH) D production could contribute to the bone demineralization in HIV patients.

1 February 2006 in Current Opinion in Genetics & Development
Verified
Journal Article
Closed access
MVMarcos Vidal
Marcos Vidal
RCRoss L Cagan
Ross L Cagan